Soft tissue infections can affect the skin, subcutaneous tissue, fascia, and muscle. These infections develop when there is a break in the skin, such as a wound or injury, that allows a microbe to enter. A weakened immune system greatly increases the risk of developing this condition. Our soft tissue infection studies aim to determine the efficacy of novel therapeutics.

Procedure
We have established a soft tissue infection model in mice in which animals are challenged with a pathogen via intramuscular (IM) injection in one or both quadriceps muscles. Test article may be administered via oral gavage (PO) or subcutaneous (SC), intravenous (IV), or intraperitoneal (IP) injection. Each study parameter (animal strain, pathogen, comparator(s), and dosing schedule) can be customized to meet client needs.

Endpoints for this study include mortality tracking and CFU burden in harvested organs and/or blood. Pharmacokinetic profiling, blood chemistry, tissue harvests, and histology are available upon request.

Sample Data

Pathogens
TransPharm has validated a thigh infection model using the following pathogens:

• Acinetobacter baumannii
  • ATCC 17961
• Enterococcus faecalis
  • EFS-007
  • ATCC 700221
  • ATCC 700802
• Escherichia coli
  • ATCC BAA-457
  • ATCC 25922
• Klebsiella pneumoniae
  • ATCC BAA-2146
• Staphylococcus aureus
  • ATCC BAA-1717 (MRSA)
  • ATCC 29213
  • USA300 (MRSA)
• Streptococcus pneumoniae
  • 02J1095
• Streptococcus pyogenes
  • ATCC 19615
  • SPI-3541

Additional validations are available upon request.